Teads Holding Co.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TEAD | FORA.TO | CARS | NNN1.F | TJGC | VSME | |
|---|---|---|---|---|---|---|
| Market cap | 27.00M | 57.87M | 682.54M | 439.42B | 322.09M | — |
| P/E (TTM) | — | — | 22.4 | 15.6 | — | — |
| Forward P/E | -0.3 | 7.3 | 5.5 | 18.0 | — | — |
| Price/book | 3.7 | 0.6 | 1.5 | 2.9 | 206.3 | — |
| Dividend yield | — | — | — | 1.31% | — | — |
| 1-year change | −82.93% | −33.59% | +14.97% | −34.83% | +1,007.29% | — |
| Today | +9.68% | +3.11% | +10.29% | +4.72% | 0.00% | +28.05% |
The closest companies by business and industry (Internet Content & Information). Prices may be delayed up to 15 min.
Latest news
All TEAD news ›Teads lets advertisers cut low-attention placements with Adelaide AU floor
Buyers get real-time Adelaide AU next to viewability and CTR on web and CTV InStream buys worldwide. No price, floor level or test data came. What is it worth? Teads today made Adelaide's AU score, a prediction of how likely an ad…
Teads and Adelaide Bring Attention-Based Media Quality Measurement and Real-Time Optimization to Teads Ad Manager
Roastbrief US New York, NY â November 3, 2026: Teads (NASDAQ: TEAD), the omnichannel outcomes platform, today announced the expansion of its partnership with Adelaide, the leader in at
Teads Launches the Next Evolution of Teads Ad Manager
Unify full-funnel strategies—from CTV reach to digital conversions—in one platform with AI-powered workflows, greater transparency, and open MCP integrations Teads (NASDAQ: TEAD), the omnichannel outcomes platform, today announced the…
First-in-human trial of TEAD inhibitor BPI-460372 shows early signals and safety limits
A first-in-human phase Ia trial reports that the covalent TEAD palmitoylation inhibitor BPI-460372 showed preliminary antitumor activity in advanced solid tumors, but cardiac toxicities and absorption-limited exposure prevented definition…
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Treatment responses by RECIST 1.1 were observed…
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
ORION CORPORATION PRESS RELEASE 21 MAY 2026 at 10:30 EEST Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting Today, Orion Pharma (Orion Corporation)…
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
In the ongoing Phase 1 study (NCT06566079; data cutoff August 14, 2026; N=36 enrolled across 15-130 mg; median prior lines 2, range 1-12; dose escalation ongoing), ISM6331 showed antitumor activity in heavily pretreated mesothelioma.…
Generative AI-Designed TEAD Inhibitor Shows 40% Response Rate in Heavily Pretreated Mesothelioma
A Phase 1 trial presented at ESMO 2026 reports a 40% objective response rate at 130 mg for ISM6331, a generative AI-designed pan-TEAD inhibitor, in heavily pretreated mesothelioma patients.
Epigenetic YAP1–TEAD–TET1 pathway drives liver cancer without driver mutations
A mouse study from Institute of Science Tokyo shows the YAP1–TEAD–TET1 epigenetic pathway can drive hepatocellular carcinoma without canonical driver gene mutations, with supporting signatures found in human Fontan-associated liver disease…
News - SETAF-AF joins G-TEAD, USAREUR-AF at AUSA to explain how operat
The U.S. Army Southern European Task Force, Africa (SETAF-AF) commander outlined how Africa is where operational problems are defined, solutions are tested in realistic conditions, and results are shared across the Army during the 2026…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.financialcontent.com3
- markets.businessinsider.com2
- ppc.land2
- themarketsdaily.com2
- beet.tv1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.